

SEQ ID No: 5 or SEQ ID No: 6 to obtain a secondary PCR product,
and

d) sequencing said secondary PCR product.

2. A method according to Claim 1, wherein said secondary PCR product is sequenced using at least one sequencing primer chosen from SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, or SEQ ID No: 12.

4. A method according to Claim 1, wherein said secondary PCR product is sequenced using at least one sequencing primer chosen from SEQ ID No: 7 SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, or SEQ ID No: 12 and wherein at least one of said sequencing primer is replaced by one or a pair of replacement primers.

5. A method according to Claim 1, wherein said secondary PCR product is sequenced using at least one sequencing primer chosen from primers up to 1, 2, 3 or 4 nucleotides upstream or downstream primer regions chosen from SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, or SEQ ID No: 12.

6. A method according to Claim 1, wherein the outer primer is chosen from primers up to 1, 2, 3 or 4 nucleotides upstream or downstream primer regions chosen from SEQ ID No: 1 or SEQ ID No: 2.

7. A method according to Claim 1, wherein the inner primer is chosen from primers up to 1, 2, 3 or 4 nucleotides upstream or downstream primer regions chosen from SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5 or SEQ ID No: 6.

Seq. List placed before Cl. B3
REMARKS

Claims 1-20 are pending in this application. Claims 10-20 have been withdrawn from consideration. Claims 1, 2, 5, 6 and 7 have been amended to clarify the claim language and more specifically what was meant by the phrase "as represented in." Claim 4 has been amended to correct its dependency. The claims were not amended to overcome prior art and the scope of the claims were not changed by this amendment. Support for the amendments can be found in the specification as filed. No new matter has been added.